Serum miRNA-186-3P and miRNA-382-3P constitute a novel Diagnostic miRNA signature for palindromic rheumatism
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA1218265 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR32195244.fastq.gz | Fastqsanger.gz | |||
| SRR32195245.fastq.gz | Fastqsanger.gz | |||
| SRR32195246.fastq.gz | Fastqsanger.gz | |||
| SRR32195247.fastq.gz | Fastqsanger.gz | |||
| SRR32195248.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 10 |
Similar Datasets
Project description:Background: Palindromic rheumatism (PR) is a unique disease characterized by the intermittent inflammation of different joints that may progress to a variety of immune-related diseases. Unclear diagnostic criteria have limited the research on its pathogenesis and treatment options. Recently, microRNAs (miRNAs) have been used in the diagnosis of various diseases; however, the role of miRNAs in PR diagnosis remains unexplored. Using next-generation high-throughput sequencing (NGS), this study aimed to screen miRNAs specifically expressed in the serum of patients with PR to construct a diagnostic signature and verify its diagnostic efficacy. Methods: Patients with PR (N=4), patients with rheumatoid arthritis (RA; N=3), and healthy controls (N=3) were included in an exploration cohort. Differentially expressed miRNAs were screened using NGS to construct diagnostic signatures and bioinformatics tools were used to perform target gene enrichment analysis of the top 25 differentially expressed miRNAs, both upregulated and downregulated. RT-qPCR was used to verify the differential expression of the diagnostic signatures in the three validation cohorts of patients with PR (N=27) and RA (N=30), and healthy controls (N=31), and the diagnostic efficiency of the diagnostic signatures was evaluated using receiver operator characteristic (ROC) curves. Results: A total of 130 differentially expressed miRNAs–35 upregulated and 95 downregulated miRNAs–were found in the PR exploration cohort, which differed between both RA and healthy controls. miRNA-186-3p showed the largest upregulated difference, and miRNA-382-3p showed the largest downregulated difference, and consequently, were selected to construct the diagnostic signature. In the ROC analysis of the validation cohort, the diagnostic signature produced an area under the ROC curve (AUC) of 1 (95% CI 1.000-1.000) compared with healthy controls. For patients with RA, the diagnostic signature produced an AUC of 0.915 (95% CI 0.842-0.988). However, miRNA-186-3p and miRNA-382-3p levels were not associated with disease activity in patients with PR. Conclusion: A diagnostic signature comprising miRNA-186-3p and miRNA-382-3p can effectively diagnose and differentiate PR from RA. This study provides a basis for the creation of a clinical miRNA signature for the diagnosis of PR.
2025-02-02 | GSE288542 | GEO
Project description:Primary Myelofibrosis (PMF) is a Philadelphia negative chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, enhanced oxidative stress and high levels of serum pro-inflammatory cytokines. To identify genes and miRNAs potentially involved in PMF pathogenesis, we have previously carried out an integrative analysis of gene and microRNA expression profiles of PMF hematopoietic stem cells (HSPCs), which allowed us to identify miR-382-5p as up-regulated miRNA (Norfo R. et al, Blood 2014). Overexpression experiments in normal CD34+ cells have already demonstrated its central role in HSPC fate decision toward granulocyte lineage (Zini R. et al, Stem Cell Dev 2016). In this study, to further characterized the role of miR-382-5p in PMF pathogenesis, we performed a gene expression profile analysis in normal CD34+ HSPCs overexpressing miR-382-5p. Among the down-regulated genes upon miR-382-5p upregulation, we selected the anti-oxidant superoxide dismutase 2 (SOD2), depicted as the most favorable predicted target by TatgetScan 7.0. Firstly, luciferase reporter assay confirmed SOD2 as a real target of miR-382-5p. Furthermore, we showed that enforced miR-382-5p expression in CD34+ cells reduced SOD2 expression and activity, induced ROS accumulation, and oxidative DNA damages, as well as enhanced CD34+ cell proliferation. Afterwards, to confirm miR-382-5p as a key player in PMF pathogenesis, we performed inhibition experiments in PMF CD34+ cells revealing that miR-382-5p silencing restored SOD2 expression and activity, induced ROS disposal, decreased DNA oxidation and impaired cell proliferation.
2019-09-04 | GSE103464 | GEO
Project description:Sinorhizobium meliloti 382 Resequencing
| PRJNA501533 | ENA
Project description:Proper mitochondrial function plays a central role in cellular metabolism. Various diseases as well as aging are associated with diminished mitochondrial function. Previously, we identified 19 miRNAs putatively involved in the regulation of mitochondrial metabolism in skeletal muscle, a highly metabolically active tissue. In the present study, these 19 miRNAs were individually silenced in C2C12 myotubes using antisense oligonucleotides, followed by measurement of the expression of 27 genes known to play a major role in regulating mitochondrial metabolism. Based on the outcomes, we then focused on miR-382-5p and identified pathways affected by its silencing using microarrays, investigated protein expression and studied cellular respiration. Silencing of miRNA-382-5p significantly increased the expression of several genes involved in mitochondrial dynamics and -biogenesis. Microarray analysis of C2C12 myotubes silenced for miRNA-382-5p revealed a collective downregulation of mitochondrial ribosomal proteins and respiratory chain proteins. This effect was accompanied by an imbalance between mitochondrial proteins encoded by the nuclear and mitochondrial DNA (1.35-fold, p<0.01) and an induction of HSP60 protein (1.31-fold, p<0.05), indicating activation of the mitochondrial unfolded protein response (mtUPR). Furthermore, silencing of miR-382-5p reduced basal oxygen consumption rate by 14% (p<0.05) without affecting mitochondrial content, pointing towards a more efficient mitochondrial function as a result of improved mitochondrial quality control. Taken together, silencing of miR-382-5p induces a mitonuclear protein imbalance and activates the mtUPR in skeletal muscle, a phenomenon that was previously associated with improved longevity.
2018-08-28 | GSE116786 | GEO
Project description:Increasing evidence suggests that global downregulation of miRNA expression is a hallmark of human cancer, potentially due to defects in the miRNA processing machinery. In this study, we found that the protein expression of Argonaute 2 (AGO2), a key regulator of miRNA processing, was downregulated in colorectal cancer (CRC) tissues, which was also consistent with the findings of the Clinical Proteomic Tumor Analysis Consortium (CPTAC). Furthermore, the correlation between the levels of AGO2 and epithelial-mesenchymal transition (EMT) markers (E-cadherin and vimentin) indicated that reduced levels of AGO2 promoted EMT in CRC. Low expression of AGO2 was an indicator of a poor prognosis among CRC patients. Knockdown of AGO2 in CRC cells promoted migration, invasion and metastasis formation in vitro and in vivo but had no influence on proliferation. To provide detailed insight into the regulatory roles of AGO2, we performed integrated transcriptomic, quantitative proteomic and microRNA sequencing (miRNA-seq) analyses of AGO2 knockdown cells and the corresponding wild-type cells and identified neuropilin 1 (NRP1) as a new substrate of AGO2 via miR-185-3p. Our data provided evidence that knockdown of AGO2 resulted in a reduction of miR-185-3p expression, leading to the upregulation of the expression of NRP1, which is a direct target of miR-185-3p, and elevated CRC cell metastatic capacity. Inhibition of NRP1 or treatment with a miR-185-3p mimic successfully rescued the phenotypes of impaired AGO2, which suggested that therapeutically targeting the AGO2/miR-185-3p/NRP1 axis may be a potential treatment approach for CRC.
2021-02-11 | PXD024171 |
Project description:NTP4 modulates miRNA accumulation via asymmetric modification of miRNA-3p/5p duplex
| PRJNA634468 | ENA
Project description:Listeria monocytogenes F2-382
| PRJDB1729 | ENA
Project description:Pseudomonas sp. 382 Genome sequencing and assembly
| PRJNA413004 | ENA
Project description:Severe acute respiratory syndrome coronavirus (SARS-CoV) and the closely related SARS-CoV-2 are emergent highly pathogenic human respiratory viruses causing acute lethal disease associated with lung damage and dysregulated inflammatory responses. SARS-CoV envelope protein (E) is a virulence factor involved in the activation of various inflammatory pathways. Here, we study the contribution of host miRNAs to the virulence mediated by E protein. Small RNAseq analysis of infected mouse lungs identified miRNA-223 as a potential regulator of pulmonary inflammation, since it was significantly increased in SARS-CoV-WT virulent infection as compared to the attenuated SARS-CoV-∆E infection. In vivo inhibition of miRNA-223-3p increased mRNA levels of pro-inflammatory cytokines and NLRP3 inflammasome, suggesting that during lung infection, miRNA-223 might contribute to restrict an excessive inflammatory response. Interestingly, miRNA-223-3p inhibition also increased the levels of the CFTR transporter, which is involved in edema resolution and was significantly downregulated in the lungs of mice infected with the virulent SARS-CoV-WT virus. At the histopathological level, a decrease in the pulmonary edema was observed when miR-223-3p was inhibited, suggesting that miRNA-223-3p was involved in the regulation of the SARS-CoV-induced inflammatory pathology. These results indicate that miRNA-223 participates in the regulation of E protein mediated- inflammatory response during SARS-CoV infection by targeting different host mRNAs involved in the pulmonary inflammation and identify miRNA-223 as a potential therapeutic target in SARS-CoV infection.
2022-02-04 | GSE180563 | GEO
Project description:Arcobacter cryaerophilus 382 genome sequencing and assembly
| PRJNA294646 | ENA